BASELINE ESSDAI/DAS SCORES IN 8061 PATIENTS WITH PRIMARY SJÖGREN SYNDROME: CHARACTERIZATION OF SYSTEMIC DISEASE

P. Brito-Zerόn, N. Acar-Denizli, M. Zeher, A. Rasmussen, X. Li, C. Baldini, J.-E. Gottenberg, D. Danda, L. Quartuccio, G. Hernandez-Molina, A.A. Kruize, S.-H. Park, M. Kvarnström, S. Praprotnik, D. Sene, A. Alunno, R. Solans, T. Mandl, Y. Suzuki, M. Rischmueller, G. Nordmark, G. Fraile, P. Wiland, H. Bootsma, T. Nakamura, V. Valim, R. Giacomelli, R. Seror, V. Devauchelle-Pensec, B. Hofauer, M. Bombardieri, V. Trevisani, D. Hammenfors, A. Minniti, S.G. Pasoto, J. Morel, S. Retamozo, T.A, Gheita, F. Atzeni, C. Vollenveider, X. Mariette, M. Ramos-Casals, on behalf of EULAR-SS TF Big Data ConsortiumHosp CIMA-Sanitas Hosp Clínic, Barcelona, Spain Msgsü, Istanbul, Turkey Univ, Debrecen, Hungary OMRF, Oklahoma, United States Anhui Hosp, Hefei, China Univ, Pisa, Italy Univ, Strasbourg, France CMC, Vellore, India Santa Maria, Udine, Italy INCMNSZ, México, Mexico UMC, Utrecht, Netherlands Catholic Univ, Seoul, Korea, Republic Of Karolinska Instit, Stockholm, Sweden UMCL, Ljubljana, Slovenia Lariboisière Hosp, Paris, France Univ, Perugia, Italy Hosp Vall Hebron, Barcelona, Spain Lund Univ, Malmö, Sweden Univ, Kanazawa, Japan TQEH, Adelaide, Australia Univ, Uppsala, Sweden Hosp Ramόn Cajal, Madrid, Spain Med Hosp, Wroclaw, Poland Univ, Groningen, Netherlands Univ, Nagasaki, Japan UFES, Vitόria, Brazil Univ, L'Aquila, Italy Univ Sud, Paris Univ, Brest, France TUM, München, Germany QMUL, London, United Kingdom UNIFESP, Sao Paulo, Brazil Haukeland Hosp, Bergen, Norway Sapienza Univ, Rome, Italy USP, Sao Paulo, Brazil Univ, Montpellier, France INICSA, Cordoba, Argentina Univ, Cairo, Egypt L.Sacco Univ, Milan, Italy German Hosp, Buenos Aires, ArgentinaObjectives: To characterize and quantify systemic involvement at diagnosis in a large international cohort of patients with primary Sjögren's syndrome (SS). Methods: The Big Data Sjögren Project was formed in 2014 to take a “high-definition” picture of primary SS at diagnosis by merging international databases (9302 consecutive patients from 21 countries of the 5 continents). The main features (including ESSDAI/DAS) at diagnosis were analysed. Results: Baseline ESSDAI was available in 8061 patients (93% female, mean age 53yrs). The mean ESSDAI score at diagnosis of the entire cohort was 6.4±7.9. In 1498 patients (19%), score at diagnosis was 0, while 681 (8%) presented with high activity in at least one domain. The main systemic features at diagnosis were biological (51%), articular (38%), haematological (24%) and glandular (22%). Low DAS was reported in 4480 (56%) patients, moderate DAS in 2483 (31%) and high DAS in 1098 (14%) patients. The mean baseline ESSDAI was higher the younger the patient was (p<0.001), higher in White patients (6.9 vs 5.1, p<0.001), males (8.4 vs 6.2, p<0.001), those with positive ocular (6.7 vs 4.9, p<0.001) or oral (6.8 vs 6.2, p=0.016) tests, and those with ANA (6.9 vs 4.5, p<0.001), RF (7.5 vs 5.8, p<0.001) and anti-Ro/La antibodies (7.2 vs 4.4, p<0.001). Logistic regression identified as independent variables White ethnicity (OR 3.07), abnormal ocular tests (OR 2.14), ANA (OR 1.67) and Ro/La autoantibodies (OR 2.78). Conclusions: This is the largest series of patients with primary SS in whom the ESSDAI score has been evaluated. Primary SS is undeniably a systemic disease even at the time of diagnosis, with nearly 80% of patients showing an ESSDAI score >0. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4472Citation: Annals of the Rheumatic Diseases, volume 76, supplement 2, year 2017, page 464Session: Validation of outcome measures and biomarkers (Poster Presentations )